ESMO 25: OS/PFS Win For RemeGen’s Disitamab Vedotin/Toripalimab Combo In 1L Urothelial Carcinoma

CLDN18.2-Targeted ADC RC118’s First Data Shown In Phase II

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.